What were the key drivers of 3M's financial performance in 2006?

3M's financial performance in 2006 was driven by broad-based sales growth across all six of its business segments, including Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, and Electro and Communications. Strategic acquisitions, such as CUNO and Security Printing and Systems Limited, contributed to sales growth. The company also benefited from a significant gain on the sale of its branded pharmaceuticals business. Investments in research and development also played a crucial role in supporting growth and innovation.

What impact did the sale of the pharmaceuticals business have on 3M's financial results?

The sale of 3M's global branded pharmaceuticals business in December 2006 and January 2007 resulted in a significant pre-tax gain of $1.074 billion, which positively impacted the company's net income for the year. While this divestiture streamlines the company's focus, it will create a comparability issue for future year-over-year financial results due to the absence of these pharmaceutical sales and related profitability.

How is 3M managing its capital and returning value to shareholders?

3M demonstrated a strong commitment to shareholder value in 2006. The company utilized $3.7 billion for share repurchases and dividends. Specifically, $2.351 billion was used for share repurchases under newly authorized programs, and dividends paid to stockholders totaled $1.376 billion. The company also announced a significant increase in its quarterly dividend by 4.3% in early 2007 and a substantial $7 billion share repurchase authorization for the next two years, signaling continued confidence in its financial position and future prospects.

What are the main risks facing 3M, as outlined in the filing?

3M identifies several key risk factors, including the impact of worldwide economic conditions and fluctuations in foreign currency exchange rates due to its significant international presence. Competitive conditions and evolving customer preferences are also critical, impacting demand and pricing. The company's growth is dependent on the successful timing and market acceptance of new product offerings. Additionally, fluctuations in the costs and availability of raw materials and energy, potential disruptions from acquisitions and divestitures, legal and regulatory proceedings, and the realization of productivity improvements are all noted as potential risks.

MMM 10-K FY2006 Annual Report — Revenue, Net Income, EPS

Summary

3M Company's 2006 Annual Report (Form 10-K) highlights a year of strong performance, with record net sales of $22.92 billion and record net income of $3.85 billion. This robust financial performance was driven by broad-based sales growth across all six business segments, bolstered by strategic acquisitions and consistent R&D investment. A significant event during the year was the sale of 3M's global branded pharmaceuticals business, which contributed $1.074 billion in pre-tax gains. While this divestiture streamlines the company's portfolio, it will impact year-over-year comparability in future periods. The company continued its commitment to shareholder returns through substantial share repurchases and a consistent history of dividend increases, underscoring its financial strength and commitment to shareholder value. Looking ahead, 3M plans to increase investments in R&D and capital expenditures to fuel future growth, focusing on core business reinvestment, emerging business opportunities, international expansion, and strategic acquisitions in high-growth industries. The company's diversified business model, global reach, and focus on innovation position it well for continued success.

Key Highlights

1Record Net Sales of $22.92 billion and Record Net Income of $3.85 billion in 2006.
2Divestiture of the global branded pharmaceuticals business, resulting in a significant gain of $1.074 billion pre-tax.
3Broad-based sales growth across all six business segments, indicating diversified revenue streams and market penetration.
4Significant investment in Research & Development, totaling $1.522 billion, including a $95 million in-process R&D charge, demonstrating commitment to innovation.
5Substantial capital expenditures of $1.168 billion, with planned increases for 2007 to support growth initiatives and capacity expansion.
6Strong shareholder returns through significant share repurchases totaling $2.351 billion and continued dividend payments ($1.84 per share in 2006).
7Commitment to financial strength with an AA/Aa1 credit rating and a healthy debt-to-capital ratio of 26%.

3M CO Annual Report, Year Ended Dec 31, 2006

Summary

Key Highlights

Frequently Asked Questions